siRNA及其运载系统研究进展

doi:10.16431/j.cnki.1671-7236.2017.05.004

摘要/Abstract

摘要：

小干扰RNA （small interfering RNA，siRNA）通过基因干扰技术进行有针对性的基因沉默，其控制目标基因表达的能力为基因治疗癌症和遗传性疾病提供了新的希望。但siRNA的药理性能很低，如血清稳定性低、脱靶、先天免疫反应，为临床治疗提供了一个挑战。由于负离子性能和刚性结构致使siRNA难以穿透细胞膜，因此，构建安全、稳定、高效的siRNA运载系统将siRNA运载到靶细胞的细胞质是至关重要的。作者综述了几种可增强体内外细胞摄取和靶基因沉默的广泛、发达的非病毒性siRNA运载系统，并讨论了它们的特点和进行siRNA治疗用于临床应用的机会，以期为今后siRNA的研究与临床应用奠定基础。

关键词: siRNA; 运载系统; 基因沉默

Abstract:

Small interfering RNA (siRNA) has proved to be a powerful tool for target-specific gene silencing via RNA interference (RNAi). Its ability to control targeted gene expression gives new hope to gene therapy as a treatment for cancers and genetic diseases. However,siRNA shows poor pharmacological properties, such as low serum stability,off-targeting, and innate immune responses, which present a significant challenge for clinical applications.In addition, siRNA cannot cross the cell membrane for siRNA activity because of its anionic property and stiff structure.Therefore, the development of a safe,stable,and efficient system for the delivery of siRNA therapeutics into the cytoplasm of targeted cells is crucial. Several nanoparticle platforms for siRNA delivery have been developed to overcome the major hurdles facing the therapeutic uses of siRNA. This review covers a broad spectrum of non-viral siRNA delivery systems developed for enhanced cellular uptake and targeted gene silencing in vitro and in vivo, and discusses their characteristics and opportunities for clinical applications of therapeutic siRNA,in order to lay a good foundation for the later research.

Key words: siRNA; delivery systems; gene silencing

中图分类号:

Q522

王洋, 金一. siRNA及其运载系统研究进展[J]. 《中国畜牧兽医》, 2017, 44(5): 1281-1288.

WANG Yang, JIN Yi. Research Progress on Small Interfering RNA and Its Delivery Systems[J]. , 2017, 44(5): 1281-1288.

参考文献

[1] Baulcombe D. RNA silencing in plants[J]. Nature, 2004, 431(7006):356-363.
[2] Jonesrhoades M W, Bartel D P, Bartel B. microRNAs and their regulatory roles in plants[J].Plant Biology, 2006, 57(57):19-53.
[3] Vaucheret H. Post-transcriptional small RNA pathways in plants:Mechanisms and regulations[J]. Genes & Development, 2006, 20(7):759-771.
[4] Axtell M J. Classification and comparison of small RNAs from plants[J]. Plant Biology, 2013, 64(64):137-159.
[5] Jyothi M N, Rai D V, Babu R N. Identification and characterization of high temperature stress responsive novel miRNAs in french bean (Phaseolus vulgaris)[J]. Applied Biochemistry and Biotechnology, 2015, 176(3):835-849.
[6] Voinnet O. Origin, biogenesis, and activity of plant microRNAs[J]. Cell, 2009, 136(4):669-687.
[7] Aryal R, Yang X, Yu Q, et al. Asymmetric purine-pyrimidine distribution in cellular small RNA population of papaya[J]. BMC Genomics, 2012, 13(1):1-14.
[8] Lee S R, Collins K. Physical and functional coupling of RNA-dependent RNA polymerase and Dicer in the biogenesis of endogenous siRNAs[J]. Nature Structural & Molecular Biology, 2007, 14(7):604-610.
[9] Whitehead K A, Langer R, Anderson D G. Knocking down barriers:Advances in siRNA delivery[J]. Nature Reviews Drug Discovery, 2010, 8(2):129-138.
[10] Rajagopalan R, Vaucheret H, Trejo J, et al. A diverse and evolutionarily fluid set of microRNAs in Arabidopsis thaliana[J]. Genes & Development, 2007, 20(20):3407-3425.
[11] Brodersen P, Sakvarelidze-Achard L, Bruun-Rasmussen M, et al. Widespread translational inhibition by plant miRNAs and siRNAs[J].Science, 2008, 320(5880):1185-1190.
[12] Baumberger N, Baulcombe D C. Arabidopsis ARGONAUTE1 is an RNA Slicer that selectively recruits microRNAs and short interfering RNAs[J].Proc Natl Acad Sci USA, 2005, 102(33):11928-11933.
[13] Khvorova A, Reynolds A, Leake D, et al. Methods and compositions for selecting siRNA of improved functionality:WO, US9228186[P]. 2016.
[14] Xie Z, Johansen L K, Gustafson A M, et al. Genetic and functional diversification of small RNA pathways in plants[J]. PLoS Biology, 2004, 2(2):642-652.
[15] Borsani O, Zhu J, Verslues P E, et al. Endogenous siRNAs derived from a pair of natural cis-antisense transcripts regulate salt tolerance in Arabidopsis[J]. Cell, 2005, 123(7):1279-1291.
[16] Chan S W, Zilberman D, Xie Z, et al. RNA silencing genes control de novo DNA methylation[J]. Science, 2004,303(5662):1336.
[17] Kasschau K D, Fahlgren N, Chapman E J, et al. Genome-wide profiling and analysis of Arabidopsis siRNAs[J].PLoS Biology, 2007, 5(3):e57.
[18] Xie Z, Allen E, Wilken A, et al. DICER-LIKE 4 functions in trans-acting small interfering RNA biogenesis and vegetative phase change in Arabidopsis thaliana[J]. Proc Natl Acad Sci USA, 2005, 102(36):12984-12889.
[19] Havecker E R, Wallbridge L M, Hardcastle T J, et al. The Arabidopsis RNA-directed DNA methylation argonautes functionally diverge based on their expression and interaction with target loci[J]. Plant Cell, 2010, 22(2):321-334.
[20] Qi Y, He X, Wang X J, et al. Distinct catalytic and non-catalytic roles of ARGONAUTE4 in RNA-directed DNA methylation[J]. Nature, 2006, 443(7114):1008-1012.
[21] Zilberman D, Cao X, Jacobsen S E. ARGONAUTE4 control of locus-specific siRNA accumulation and DNA and histone methylation[J].Science, 2003, 299(5607):716-719.
[22] Macrae I J, Zhou K, Li F, et al. Structural basis for double-stranded RNA processing by Dicer[J]. Science, 2006, 311(5758):195-198.
[23] Vermeulen A, Behlen L, Reynolds A, et al. The contributions of dsRNA structure to Dicer specificity and efficiency[J]. RNA, 2005, 11(5):674-682.
[24] Fernandes J C, Qiu X, Winnik F M, et al. Low molecular weight chitosan conjugated with folate for siRNA delivery in vitro:Optimization studies[J]. International Journal of Nanomedicine, 2011, 7(1):5833-5845.
[25] Pei Y, Hancock P J, Zhang H, et al. Quantitative evaluation of siRNA delivery in vivo[J]. RNA, 2010, 16(12):2553-2563.
[26] Wen Y,Meng W S. Recent in vivoevidences of particle-based delivery of small-interfering RNA (siRNA) into solid tumors[J]. Journal of Pharmaceutical Innovation, 2014, 9(2):158-173.
[27] Singh N, Agrawal A, Leung A K L, et al. Effect of nanoparticle conjugation on gene silencing by RNA interference[J]. Journal of the American Chemical Society, 2010, 132(24):8241-8253.
[28] Watts J K, Deleavey G F, Damha M J. Chemically modified siRNA:Tools and applications[J]. Drug Discovery Today, 2008, 13(19-20):842-855.
[29] Hong C A, Nam Y S. Functional nanostructures for effective delivery of small interfering RNA therapeutics[J]. Theranostics, 2014, 4(12):1211-1232.
[30] Al-Abd A M, Lee S H, Kim S H, et al. Penetration and efficacy of VEGF siRNA using polyelectrolyte complex micelles in a human solid tumor model in vitro[J].J Control Release, 2009, 137(2):130-135.
[31] Kim S H, Jeong J H, Lee S H, et al. PEG conjugated VEGF siRNA for anti-angiogenic gene therapy[J]. J Control Release, 2006, 116(2):123-129.
[32] Kim S H, Jeong J H, Lee S H, et al. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer[J].J Control Release, 2008, 129(2):107-116.
[33] Choi S W, Lee S H, Mo k H, et al. Multifunctional siRNA delivery system:Polyelectrolyte complex micelles of six-arm PEG conjugate of siRNA and cell penetrating peptide with crosslinked fusogenic peptide[J]. Biotechnology Progress, 2010, 26(1):57-63.
[34] Jung S, Lee S H, Mok H, et al. Gene silencing efficiency of siRNA-PEG conjugates:Effect of PEGylation site and PEG molecular weight[J]. J Control Release, 2010, 144(3):306-313.
[35] Oishi M, Nagasaki Y, Itaka K, et al. Lactosylated poly(ethylene glycol)-siRNA conjugate through acid-labile beta-thiopropionate linkage to construct pH-sensitive polyion complex micelles achieving enhanced gene silencing in hepatoma cells[J]. Journal of the American Chemical Society, 2005, 127(6):1624-1635.
[36] Dohmen C, Fröhlich T, Lächelt U, et al. Defined folate-PEG-siRNA conjugates for receptor-specific gene silencing[J]. Molecular Therapy Nucleic Acids, 2012, 1(1):e7.
[37] Nothisen M, Kotera M, Voirin E, et al. Cationic siRNAs provide carrier-free gene silencing in animal cells[J]. Journal of the American Chemical Society, 2009, 131(131):17730-17731.
[38] Perche P, Nothisen M, Bagilet J, et al. Cell-penetrating cationic siRNA and lipophilic derivatives efficient at nanomolar concentrations in the presence of serum and albumin[J].J Control Release, 2013, 170(1):92-98.
[39] Rozema D B, Lewis D L, Wakefield D H, et al. Dynamic polyconjugates for targeted in vivo delivery of siRNA to hepatocytes[J]. Proc Natl Acad Sci USA, 2007, 104(32):12982-12987.
[40] Meyer M, Dohmen C, Philipp A, et al. Synthesis and biological evaluation of a bioresponsive and endosomolytic siRNA-polymer conjugate[J].Molecular Pharmaceutics, 2009, 6(3):752-762.
[41] Lee J Y, Lee S H, Oh M H, et al. Prolonged gene silencing by siRNA/chitosan-g-deoxycholic acid polyplexes loaded within biodegradable polymer nanoparticles[J]. J Control Release, 2012, 162(2):407-413.
[42] Lee S H, Mok H, Lee Y, et al. Self-assembled siRNA-PLGA conjugate micelles for gene silencing[J]. J Control Release, 2011, 152(1):152-158.
[43] Park K, Yang J A, Lee M Y, et al. Reducible hyaluronic acid-siRNA conjugate for target specific gene silencing[J]. Bioconjugate Chemistry, 2013, 24(7):1201-1209.
[44] Kim J S, Mi H O, Park J Y, et al. Protein-resistant, reductively dissociable polyplexes for in vivo, systemic delivery and tumor-targeting of siRNA[J].Biomaterials, 2013, 34(9):2370-2379.
[45] Namgung R, Kim W J. A highly entangled polymeric nanoconstruct assembled by siRNA and its reduction-triggered siRNA release for gene silencing[J]. Small, 2012, 8(20):3209-3219.
[46] Hong C A, Kim J S, Lee S H, et al. Reductively dissociable siRNA-polymer hybrid nanogels for efficient targeted gene silencing[J]. Advanced Functional Materials, 2013, 23(3):316-322.
[47] Zimmermann T S, Lee A C, Akinc A, et al. RNAi-mediated gene silencing in non-human primates[J].Nature, 2006, 441(7089):111-114.
[48] Akinc A, Goldberg M, Qin J, et al. Development of lipidoid-siRNA formulations for systemic delivery to the liver[J]. Mol Ther, 2009, 17(5):872-879.
[49] Sperling R A, Rivera G P, Zhang F, et al. Biological applications of gold nanoparticles[J]. Chemical Society Reviews, 2008, 37(9):1896-1908.
[50] Novina C D, Sharp P A. The RNAi revolution[J]. Nature, 2004, 430(6996):161-164.
[51] Yin H, Kanasty R L, Eltoukhy A A, et al. Non-viral vectors for gene-based therapy[J].Nature Reviews Genetics, 2014, 15(8):541-555.
[52] Liu S, Asparuhova M, Brondani V, et al. Inhibition of HIV-1 multiplication by antisense U7 snRNAs and siRNAs targeting cyclophilin A[J]. Nucleic Acids Research, 2004, 32(12):3752-3759.
[53] Lee S H, Yun S, Lee J, et al. RasGRP1 is required for human NK cell function[J]. Journal of Immunology, 2009, 183(183):7931-7938.
[54] Lee S H, Yun S, Piao Z H, et al. Suppressor of cytokine signaling 2 regulates IL-15-primed human NK cell function via control of phosphorylated Pyk2[J]. Journal of Immunology, 2010, 185(2):917-928.
[55] Bedel R, Thiery-vuillemin A, Grandclement C, et al. Novel role for STAT3 in transcriptional regulation of NK immune cell targeting receptor MICA on cancer cells[J]. Cancer Research, 2011, 71(5):1615-1626.
[56] Lozano E, Dominguez-villar M, Kuchroo V, et al. The TIGIT/CD226 axis regulates human T cell function[J]. Journal of Immunology, 2012, 188(8):3869-3875.
[57] Fenizia C, Fiocchi M, Jones K, et al. Human T-cell leukemia/lymphoma virus type 1 p30, but not p12/p8, counteracts Toll-like receptor 3(TLR3) and TLR4 signaling in human monocytes and dendritic cells[J]. Journal of Virology, 2014, 88(1):393-402.